🔥🐔 BizChicken 🐔🔥
Companies Similar to Outlook Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Alnylam Pharmaceuticals, Inc.
ONPATTRO
Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. It targets genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases.
About | Leadership | DEI | About | About | About | About | About | About | Contact | Careers | Careers | Careers | Careers | Jobs | News | News | Careers | Careers | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Culture | Jobs | About | News | News | News | News | Careers | News | News | Careers | About | About | About | About | About | About | About | Jobs | About
Symbol: ALNY
Recent Price: $236.01
Industry: Biotechnology
CEO: Dr. Yvonne L. Greenstreet M.B.A., MBChB
Sector: Healthcare
Employees: 2100
Address: 675 West Kendall Street, Cambridge, MA 02142
Phone: 617 551 8200
Leadership
- Yvonne Greenstreet, Chief Executive Officer
- Pushkal Garg, Chief Medical Officer
- Jeff Poulton, Chief Financial Officer
- Kelley Boucher, Chief Human Resource Officer
- Timothy Maines, Chief Technical Operations and Quality Officer
- Tolga Tanguler, Chief Commercial Officer
- Piyush Sharma, Chief Ethics & Compliance Officer
- Evan Lippman, Chief Corporate Development & Strategy Officer
- Kevin Fitzgerald, Chief Scientific Officer
- Amy W. Schulman, Chair
- Dennis A. Ausiello,
- Carolyn Bertozzi,
- Michael W. Bonney,
- Olivier Brandicourt,
- Margaret A. Hamburg,
- Peter N. Kellogg,
- David E.I. Pyott,
- Colleen F. Reitan,
- Phillip A. Sharp,
- Elliott Sigal,
Last updated: 2024-12-31
Applied Therapeutics, Inc.
AT-007
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products targeting cardiovascular disease, galactosemia, and diabetic complications. Key products include AT-007 and AT-001.
About | Leadership | Leadership | Leadership | Leadership | Vision/Values | Culture | DEI | Contact | Contact | Careers | Careers | About | About | About
Symbol: APLT
Recent Price: $0.81
Industry: Biotechnology
CEO: Dr. Shoshana Shendelman Ph.D.
Sector: Healthcare
Employees: 31
Address: 545 Fifth Avenue, New York, NY 10017
Phone: 212 220 9226
Leadership
- Shoshana Shendelman, Chair, Board of Directors
- Riccardo Perfetti, Chief Medical Officer
- Les Funtleyder,
- Dale Hooks, Chief Commercial Officer
- Constantine Chinoporos, Chief Business Officer / Chief Operating Officer
- Joel Marcus,
- Jay Skyler,
- Stacy Kanter,
- Teena Lerner,
- Donald Landry M.D., Ph.D., Chair, Scientific Advisory Board
- Roy Freeman M.D.,
- Roxana Mehran M.D.,
- Lawrence Steinman M.D.,
- Gregg Stone M.D.,
- Donald d'Amico M.D.,
- Donald Landry, Chair, Scientific Advisory Board
- Roy Freeman,
- Roxana Mehran,
- Lawrence Steinman,
- Gregg Stone,
- Donald d'Amico,
Last updated: 2024-12-31
Candel Therapeutics, Inc.
CAN-2409, CAN-3110
Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.
About | About | About | About | Contact | Careers | Careers | About | About | About | Careers | About
Symbol: CADL
Recent Price: $7.95
Industry: Biotechnology
CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Sector: Healthcare
Employees: 42
Address: 117 Kendrick Street, Needham, MA 02494
Phone: 617 916 5445
Last updated: 2024-12-31
Omeros Corporation
Narsoplimab
Omeros Corporation is a commercial-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for inflammation, immune-related cancers, and addictive disorders.
Symbol: OMER
Recent Price: $9.74
Industry: Biotechnology
CEO: Dr. Gregory A. Demopulos M.D.
Sector: Healthcare
Employees: 198
Address: The Omeros Building, Seattle, WA 98119
Phone: 206 676 5000
Last updated: 2024-12-31
Oncternal Therapeutics, Inc.
zilovertamab, ONCT-216, ONCT-808, ONCT-534
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.
Symbol: ONCT
Recent Price: $0.53
Industry: Biotechnology
CEO: Dr. James B. Breitmeyer M.D., Ph.D.
Sector: Healthcare
Employees: 27
Address: 12230 El Camino Real, San Diego, CA 92130
Phone: 858 434 1113
Last updated: 2024-12-31
Atossa Therapeutics, Inc.
Endoxifen
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for oncology and infectious diseases with key programs in breast cancer and COVID-19 treatment.
Symbol: ATOS
Recent Price: $0.97
Industry: Biotechnology
CEO: Dr. Steven C. Quay FCAP, M.D., Ph.D.
Sector: Healthcare
Employees: 12
Address: 107 Spring Street, Seattle, WA 98104
Phone: 206 588 0256
Last updated: 2024-12-31
Celldex Therapeutics, Inc.
therapeutic monoclonal and bispecific antibodies
Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and cancers.
About | About | Management | Directors | About | Contact | About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About
Symbol: CLDX
Recent Price: $25.12
Industry: Biotechnology
CEO: Mr. Anthony S. Marucci M.B.A.
Sector: Healthcare
Employees: 160
Address: Perryville III Building, Hampton, NJ 08827
Phone: 908 200 7500
Leadership
- Anthony S. Marucci, Founder, President, Chief Executive Officer and Director
- Tibor Keler, Ph.D., Founder, Executive Vice President and Chief Scientific Officer
- Diane C. Young, M.D., Senior Vice President and Chief Medical Officer
- Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
- Sam Martin, Senior Vice President and Chief Financial Officer
- Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer
- Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer
- Sarah Cavanaugh, Senior Vice President, Corporate Affairs and Administration
- Margo Heath-Chiozzi, M.D., Senior Vice President, Regulatory Affairs
- Freddy A. Jimenez, Esq., Senior Vice President and General Counsel
- Karen L. Shoos, J.D., Former Chair, Director of Operations, Maryland Tech Council Venture Mentoring Services Program
- Keith L. Brownlie, Former Partner, Ernst & Young LLP
- Herbert J. Conrad, Former President, Roche Pharmaceuticals US
- James J. Marino, J.D., Former Partner, Dechert LLP
- Harry H. Penner, Jr., J.D., L.L.M., Former Chairman and CEO, Nascent Bioscience
- Cheryl L. Cohen, President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
- Dr. Garry Neil, Chief Executive Officer; Chair of the Board, Avalo Therapeutics
- Rita Jain, M.D., Former Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc.
- Carl June, M.D.,
- Michel Nussenzweig, M.D., Ph.D.,
- Marc E. Rothenberg M.D., Ph.D.,
- Joseph Schlessinger, Ph.D.,
- Louis Weiner, M.D.,
Last updated: 2024-12-31
Compass Therapeutics, Inc.
CTX-009, CTX-471, CTX-8371
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.
Symbol: CMPX
Recent Price: $1.48
Industry: Biotechnology
CEO: Dr. Thomas J. Schuetz M.D., Ph.D.
Sector: Healthcare
Employees: 32
Address: 80 Guest Street, Boston, MA 02135
Phone: 617 500 8099
Last updated: 2024-12-31
Context Therapeutics Inc.
onapristone extended release (ONA-XR)
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for women in the United States. Its main product, ONA-XR, is aimed at resistant female hormone-dependent cancers.
Symbol: CNTX
Recent Price: $1.06
Industry: Biotechnology
CEO: Mr. Martin A. Lehr
Sector: Healthcare
Employees: 5
Address: 2001 Market Street, Philadelphia, PA 19103
Phone: 267 225 7416
Last updated: 2024-12-31
Cardiff Oncology, Inc.
Onvansertib
Cardiff Oncology, Inc. is a clinical-stage oncology company developing treatment medicine for cancer patients, featuring lead drug candidate onvansertib, targeting various cancers including colorectal cancer. The company is headquartered in San Diego, California.
Symbol: CRDF
Recent Price: $4.26
Industry: Biotechnology
CEO: Dr. Mark Erlander Ph.D.
Sector: Healthcare
Employees: 31
Address: 11055 Flintkote Avenue, San Diego, CA 92121
Phone: 858 952 7570
Last updated: 2024-12-31
Immunome, Inc.
IMM-ONC-01, IMM-BCP-01
Immunome, Inc. is a biopharmaceutical company focused on developing antibody therapeutics for oncology and infectious diseases, offering innovative solutions such as IMM-ONC-01 for cancer and IMM-BCP-01 for COVID-19 treatment.
Symbol: IMNM
Recent Price: $10.28
Industry: Biotechnology
CEO: Dr. Clay B. Siegall Ph.D.
Sector: Healthcare
Employees: 78
Address: 665 Stockton Drive, Exton, PA 19341
Phone: 610 321 3700
Last updated: 2024-12-31
Kiora Pharmaceuticals, Inc.
KIO-301
Kiora Pharmaceuticals, Inc. develops therapies for ophthalmic diseases, with lead product KIO-301 in Phase 1 trial for vision restoration in degenerative retinal diseases and other products in trials for conditions like rheumatoid arthritis-related ocular issues and corneal wound repair.
Symbol: KPRX
Recent Price: $3.30
Industry: Biotechnology
CEO: Dr. Brian M. Strem Ph.D.
Sector: Healthcare
Employees: 12
Address: 1371 East 2100 South, Salt Lake City, UT 84105
Phone: 781 788 8869
Last updated: 2024-12-31
Ocean Biomedical, Inc.
Humanized Monoclonal Antibodies, Small Molecule Candidates, Malaria Vaccine
Ocean Biomedical, Inc. is a biopharmaceutical company that develops therapeutic products for oncology, fibrosis, infectious diseases, and inflammation, with a focus on innovative treatments like monoclonal antibodies targeting Chi3l1 and small molecules targeting Chit1.
Symbol: OCEA
Recent Price: $0.60
Industry: Biotechnology
CEO: Dr. Jack A. Elias M.D.
Sector: Healthcare
Employees: 9
Address: Room 325, 55 Claverick Street, Providence, RI 02903
Phone: 401-444-7375
Last updated: 2024-12-31
Outlook Therapeutics, Inc.
ONS-5010
Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing monoclonal antibodies for ophthalmic indications, with its lead product candidate ONS-5010 in Phase-III clinical trial for treating wet age-related macular degeneration and other retina diseases.
About | About | Leadership | Directors | About | Contact | Careers | Careers | Careers | Jobs | About | About
Symbol: OTLK
Recent Price: $1.86
Industry: Biotechnology
CEO: Mr. C. Russell Trenary III
Sector: Healthcare
Employees: 24
Address: Building F, Iselin, NJ 08852
Phone: 609 619 3990
Leadership
- Randy Thurman, Executive Chairman
- Yezan Haddadin, Member of the Board of Directors
- Kurt J. Hilzinger, Member of the Board of Directors
- Julia A. Haller, MD, Member of the Board of Directors
- C. Russell Trenary III, President, Chief Executive Officer, and Member of the Board
- Lawrence A. Kenyon, Chief Financial Officer and Member of the Board
- Faisal G. Sukhtian, Executive Director
- Julian Gangolli, Member of the Board of Directors
- Gerd Auffarth, MD, Member of the Board of Directors
- Andong Huang, Vice President, Business Development
Last updated: 2024-12-31
Ovid Therapeutics Inc.
OV101, OV329, OV350, OV882, OV815
Ovid Therapeutics Inc., a biopharmaceutical company based in New York, is dedicated to developing impactful medicines for neurological disorders. They have a range of drug candidates like OV101 and are involved in various clinical trials.
Our Story | Leadership | Directors | About | Our Story | Contact | About | About | About | About | About | Culture | Culture | Vision/Values | Culture | About | Culture | Culture | About | Jobs | Careers | Careers | Jobs | About | About | About | Careers | Vision/Values | About | About | About | About | About | About
Symbol: OVID
Recent Price: $0.96
Industry: Biotechnology
CEO: Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Sector: Healthcare
Employees: 40
Address: 1460 Broadway, New York, NY 10036
Phone: 646 661 7661
Leadership
- Jeremy M. Levin, D.Phil, MB BChir, Chief Executive Officer and Chairman
- Meg Alexander, President and Chief Operating Officer
- Zhong Zhong, Ph.D., Chief Scientific Officer
- Jeffrey Rona, Chief Business and Financial Officer
- Amanda Banks, M.D., Chief Development Officer
- Julia Tsai, Ph.D., Senior Vice President of Clinical Development
- Karen Bernstein, Ph.D., Director, Chair of the Compensation Committee, Member of the Audit and Nominating and Corporate Governance Committees
- Barbara G. Duncan, MBA, Director, Chair of the Audit Committee, Member of the Nominating and Corporate Governance Committee
- Bart Friedman, J.D., Lead Independent Director, Chair of the Nominating and Corporate Governance Committee, Member of the Audit and Compensation Committees
- Michael Poole, M.D., FACP, Director, Member of the Audit and Compensation Committees
- Kevin Fitzgerald, Ph.D., Director, Member of the Nominating and Corporate Governance Committee
Last updated: 2024-12-31
Phio Pharmaceuticals Corp.
INTASYL therapeutic platform
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.
Symbol: PHIO
Recent Price: $1.90
Industry: Biotechnology
CEO: Mr. Robert J. Bitterman
Sector: Healthcare
Employees: 8
Address: 257 Simarano Drive, Marlborough, MA 01752
Phone: 508 767 3861
Last updated: 2024-12-31
Relay Therapeutics, Inc.
RLY-4008, RLY-2608, RLY-1971
Relay Therapeutics, Inc. is a clinical-stage company that focuses on precision medicine in oncology and genetic diseases by transforming the drug discovery process. Their leading products include small molecule inhibitors for advanced cancer treatment.
Symbol: RLAY
Recent Price: $4.18
Industry: Biotechnology
CEO: Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Sector: Healthcare
Employees: 323
Address: 399 Binney Street, Cambridge, MA 02139
Phone: 617 370 8837
Last updated: 2024-12-31
Sonnet BioTherapeutics Holdings, Inc.
SON-1010, SON-080
Sonnet Bio Therapeutics Holdings, Inc. is a clinical stage oncology-focused biotechnology company developing biologic medicines using its human albumin binding technology. The company is based in Princeton, New Jersey, and has lead candidates such as SON-1010 for non-small cell lung cancer, and SON-080 for neuropathies.
Symbol: SONN
Recent Price: $1.48
Industry: Biotechnology
CEO: Dr. Pankaj Mohan Ph.D.
Sector: Healthcare
Employees: 12
Address: 100 Overlook Center, Princeton, NJ 08540
Phone: 609-375-2227
Leadership
- Pankaj Mohan, Ph.D., Founder, CEO & Chairman
- Jay Cross, Chief Financial Officer
- John K. Cini, Ph.D., Chief Scientific Officer & Co-Founder
- Susan Dexter, Chief Technical Officer
- Richard Kenney, M.D., Chief Medical Officer
- Albert Dyrness, Board Member
- Nailesh Bhatt, Chief Executive Officer & Board Member
- Raghu Rao, Board Member
- Donald Griffith, Financial Controller
- Lori McNeill, Board Member
Last updated: 2024-12-31
Stoke Therapeutics, Inc.
STK-001, STK-002
Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines to treat genetic diseases. Their lead product, STK-001, is aimed at treating Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.
Symbol: STOK
Recent Price: $10.80
Industry: Biotechnology
CEO: Dr. Edward M. Kaye M.D., Ph.D.
Sector: Healthcare
Employees: 110
Address: 45 Wiggins Avenue, Bedford, MA 01730
Phone: 781 430 8200
Leadership
- Edward M. Kaye, M.D., Chief Executive Officer & Director
- Jonathan Allan, J.D., General Counsel
- Isabel Aznarez, Ph.D., Senior Vice President, Discovery Research and Co-Founder
- Jason Hoitt, Chief Commercial Officer
- Dawn Kalmar, Chief Communications Officer
- Tommy Leggett, Chief Financial Officer
- Shamim Ruff, Chief Regulatory Officer
- Barry S. Ticho, M.D., Ph.D., FACC, Chief Medical Officer
- Joan Wood, Chief Human Resources Officer
- Adrian Krainer, Ph.D., Co-founder & Director
- Arthur Tzianabos, Ph.D., Chairman
- Jennifer Burstein, MBA, CPA, Director
- Seth L. Harrison, M.D., Director
- Arthur Levin, Ph.D., Director
- Garry E. Menzel, Ph.D., MBA, Director
- Ian F. Smith, Director
- Julie Anne Smith, Director
Last updated: 2024-12-31
Terns Pharmaceuticals, Inc.
TERN-101, TERN-201, TERN-501, TERN-601
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity, incorporating products like TERN-101, TERN-201, TERN-501, and TERN-601.
About | Contact | Careers | Careers | Careers | About | About | Careers | Culture | About | Leadership | About
Symbol: TERN
Recent Price: $7.15
Industry: Biotechnology
CEO: Ms. Amy L. Burroughs M.B.A.
Sector: Healthcare
Employees: 66
Address: 1065 East Hillsdale Boulevard, Foster City, CA 94404
Phone: 650 525 5535
Last updated: 2024-11-08